In a small, short duration trial (12 weeks), a new medication called DR10624 reduced triglyceride levels in most patients with severe hypertriglyceridemia by more than 60%, according to a preliminary late-breaking science presentation today at the American Heart Association’s Scientific Sessions 2025. The meeting, Nov. 7-10, in New Orleans, is a premier global exchange of the latest scientific advancements, research and evidence-based clinical practice updates in cardiovascular science.

The study was designed to test whether DR10624 could safely and effectively lower very high levels of lipids in the blood or triglycerides in people with severe hypertriglyceridemia (500-2,000 mg/dL), who may be at high risk of cardiovascular disease or pancreatitis due to elevated triglycerides. H

See Full Page